Lung surfactants are instilled into the respiratory system of premature infants who do not have enough surfactant to ensure alveolar expansion. Learn about lung surfactants in this nursing pharmacology guide.
Lung Surfactants: Generic and Brand Names
Here is a table of the most commonly encountered lung surfactants, their generic names, and brand names:
|Classification||Generic name||Brand name|
Disease Spotlight: Respiratory Distress Syndrome
Respiratory distress syndrome (RDS) causes obstruction at the alveolar level.
- It is frequently seen in premature infants who are delivered before their lungs have fully developed and while surfactant levels are still very low.
- A surfactant is necessary for lowering the surface tension in the alveoli so that they can stay open to allow the flow of gases.
- If surfactant levels are low, the alveoli do not expand and cannot receive air, leading to decreased gas exchange, low oxygen levels, and generalized distress throughout the body as cells do not receive oxygen that they need to survive.
- Treatment is aimed at instilling surfactant to prevent atelectasis and to allow the lungs to expand.
- Acute respiratory distress syndrome (ARDS) is characterized by progressive loss of lung compliance and increasing hypoxia.
- This syndrome typically results from a severe insult to the body, such as cardiovascular collapse, major burns, severe trauma, or rapid depressurization.
- Treatment of ARDS involves the reversal of the underlying cause of the problem combined with ventilation support.
What are Lung surfactants?
Lung surfactants are naturally occurring compounds or lipoproteins containing lipids and apoproteins that reduce the surface tension within the alveoli, allowing expansion of the alveoli for gas exchange.
The desired actions of lung surfactants include:
- Used to replace the surfactant that is missing in the lungs of neonates with RDS.
Indications of Lung surfactants
Lung surfactants are indicated for the following:
- Rescue treatment of infants who have RDS.
- Prophylactic treatment of infants at high risk for development of RDS (birth weight of <1, 350g, birth weight >1, 350g who have evidence of respiratory immaturity).
- This drug is being tried in the treatment of adult RDS and with adults after near drowning.
These drugs are instilled directly into the trachea and begin to act immediately on instillation.
|T 1/2: Unknown|
|Metabolization: Surfactant pathways|
Contraindications and Cautions
Because lung surfactants are used as emergency drugs in newborn, there are no contraindications.
Adverse effects from the use of lung surfactants include:
- Cardiovascular: Patent ductus arteriosus, bradycardia, intraventricular hemorrhage, hypotension.
- Respiratory: Pneumothorax, pulmonary air leak, pulmonary hemorrhage, apnea.
- Systemic: Sepsis, infection.
Nursing considerations for Lung surfactants
Nursing considerations for patients taking lung surfactants include:
History taking and physical exam of patients using lung surfactants include the following:
- Assess for possible contraindications and cautions: screen for the time of birth and exact weight to determine appropriate doses; because this drug is used as an emergency treatment, there are no contraindications to screen for.
- Perform a physical examination to establish baseline data for assessing the effectiveness of the drug and the occurrence of any adverse effects associated with drug therapy.
- Assess the skin temperature and color to evaluate perfusion.
- Monitor respirations, adventitious sounds, endotracheal tube placement and patency, and chest movements to evaluate the effectiveness of the drug and drug delivery.
- Evaluate blood pressure, pulse, and arterial pressure to monitor the status of the infant.
- Evaluate blood gases and oxygen saturation to monitor drug effectiveness.
- Assess temperature and complete blood count to monitor for sepsis.
Nursing Diagnosis and Care Planning
Nursing diagnosis related to drug therapy of lung surfactants might include the following:
- Decreased cardiac output related to cardiovascular and respiratory effects of the drug.
- Risk for injury related to prematurity and risk of infection.
- Ineffective airway clearance related to the possibility of mucus plugs.
- Deficient knowledge regarding drug therapy (for parents).
Nursing Implementation with Rationale
The nursing interventions for patients using lung surfactants include the following:
- Patient monitoring. Monitor the patient continuously during administration and until stable to provide life support measures as needed.
- Correct endotracheal tube placement. Ensure proper placement of the endotracheal tube with bilateral chest movement and lung sounds to provide adequate delivery of the drug.
- Review proper administration of drugs. Have staff view the manufacturer’s teaching video before regular use to review the specific technical aspects of administration.
- Suction the infant. Suction the infant immediately after administration, but do not suction for 2 hours after administration unless clinically necessary, to allow the drug time to work.
- Offer support. Provide support and encouragement to the parents of the patient, explaining the use of the drug in the teaching program, to help them cope with the diagnosis and treatment of their infant.
- Continue other measures. Continue other supportive measures related to the immaturity of the infant because this is only one aspect of medical care needed for premature infants.
Evaluation of the patient using lung surfactants include the following:
- Monitor patient response to the drug (improved breathing, alveolar expansion).
- Monitor for adverse effects (pneumothorax, patent ductus arteriosus, bradycardia, sepsis).
- Evaluate the effectiveness of the teaching plan and support parents as appropriate.
- Monitor the effectiveness of other measures to support patient and stabilize the patient.
- Evaluate the effectiveness of other supportive measures related to the immaturity of the infant.
Practice Quiz: Lung surfactants
1. A nurse is preparing to give a lung surfactant to a 36 weeks old baby with a respiratory distress syndrome. Which of the following is the correct route of administration?
1. Answer: D. Intratracheal
- Option D: Lung surfactant is instilled through the catheter inserted into the newborn’s endotracheal tube.
- Options A, B, and C: Options B, C, and D are not the routes of administration for this medication.
2. A patient with acute respiratory distress syndrome (ARDS) is receiving oxygen by a nonrebreather mask, but arterial blood gas measurements still show poor oxygenation. As the nurse responsible for this patient’s care, you would anticipate a physician order for what action?
A. Administer furosemide (Lasix) 100 mg IV push stat
B. Perform endotracheal intubation and initiate mechanical ventilation
C. Call a code for respiratory arrest
D. Immediately begin continuous positive airway pressure (CPAP) via the patient’s nose and mouth
2. Answer: B. Perform endotracheal intubation and initiate mechanical ventilation.
- Option B: Usually at this stage, the patient is working very hard to breathe and may go into respiratory arrest unless health care providers intervene by providing intubation and mechanical ventilation to decrease the patient’s work of breathing.
3. The high-pressure alarm on a patient’s ventilator goes off. When you enter the room to assess the patient, who has ARDS, the oxygen saturation monitor reads 87% and the patient is struggling to sit up. Which action should you take next?
A. Manually ventilate the patient while assessing possible reasons for the high-pressure alarm
B. Reassure the patient that the ventilator will do the work of breathing for him
C. Insert an oral airway to prevent the patient from biting on the endotracheal tube
D. Increase the fraction of inspired oxygen on the ventilator to 100% in preparation for endotracheal suctioning
3. Answer: A. Manually ventilate the patient while assessing possible reasons for the high-pressure alarm
- Option A: Manual ventilation of the patient will allow you to deliver a FiO2 of 100% to the patient while you attempt to determine the cause of the high-pressure alarm.
- Options B, C, D: The patient may need reassurance, suctioning, and/or insertion of an oral airway, but the first step should be an assessment of the reason for the high-pressure alarm and resolution of the hypoxemia.
4. To improve respiratory status, which medication should you be prepared to administer to the newborn infant with respiratory distress syndrome (RDS)?
4. Answer: C. Exosurf
- Option C: Exosurf neonatal is a form of synthetic surfactant. An infant with RDS may be given two to four doses during the first 24 to 48 hours after birth. It improves respiratory status, and research has shown a significant decrease in the incidence of pneumothorax when it is administered.
5. A nurse in the newborn nursery is monitoring a preterm newborn infant for respiratory distress syndrome. Which assessment signs, if noted in the newborn infant, would alert the nurse to the possibility of this syndrome?
A. The presence of a barrel chest with grunting
B. Hypotension and Bradycardia
C. Acrocyanosis and grunting
D. Tachypnea and retractions
5. Answer: D. Tachypnea and retractions.
- Option D: The infant with respiratory distress syndrome may present with signs of cyanosis, tachypnea or apnea, nasal flaring, chest wall retractions, or audible grunts.
Recommended resources and reference books. Disclosure: Includes Amazon affiliate links.
- Focus on Nursing Pharmacology – Easy to follow guide for Pharmacology
- NCLEX-RN Drug Guide: 300 Medications You Need to Know for the Exam – Great if you’re reviewing for the NCLEX
- Nursing 2017 Drug Handbook (Nursing Drug Handbook) – Reliable nursing drug handbook!
- Lehne’s Pharmacology for Nursing Care – Provides key information on commonly used drugs in nursing
- Pharmacology and the Nursing Process – Learn how to administer drugs correctly and safely!
- Pharm Phlash Cards!: Pharmacology Flash Cards – Flash Cards for Nursing Pharmacology
Here are other nursing pharmacology study guides:
Gastrointestinal System Drugs
Respiratory System Drugs
- Bronchodilators and Antiasthmatics
- Expectorants and Mucolytics
- Inhaled Steroids
- Lung Surfactants
Endocrine System Drugs
- Adrenocortical Agents
- Antidiabetic Agents
- Glucose-Elevating Agents
- Hypothalamic Agents
- Parathyroid Agents: Bisphosphonates, Calcitonins
- Pituitary Drugs
- Thyroid Agents
Autonomic Nervous System Drugs
- Adrenergic Agonists (Sympathomimetics)
- Adrenergic Antagonists (Sympatholytics)
- Anticholinergics (Parasympatholytics)
- Cholinergic Agonists (Parasympathomimetics)
Immune System Drugs
- Antiarthritic Drugs
- Nonsteroidal Anti-Inflammatory Drugs
- Anti-Infective Drugs
- Antineoplastic Agents
- Antiprotozoal Drugs
- Antiviral Drugs
Reproductive System Drugs
Nervous System Drugs
- Antiparkinsonism Drugs
- Antiseizure Drugs
- Anxiolytics and Hypnotic Drugs
- General and Local Anesthetics
- Muscle Relaxants
- Narcotics, Narcotic Agonists, and Antimigraine Agents
- Neuromuscular Junction Blocking Agents
- Psychotherapeutic Drugs
Cardiovascular System Drugs
- Antianginal Drugs
- Antiarrhythmic Drugs
- Antihyperlipidemic Drugs
- Antihypertensive Drugs
- Cardiotonic-Inotropic Drugs
- Drugs Affecting Coagulation
References and Sources
References and sources for this study guide about Lung Surfactants.
- Barnes, P. J., & Pedersen, S. (1993). Efficacy and safety of inhaled corticosteroids in asthma. American Review of Respiratory Disease, 148(4_pt_2), S1-S26. [Link]
- Karch, A. M., & Karch. (2011). Focus on nursing pharmacology. Wolters Kluwer Health/Lippincott Williams & Wilkins. [Link]
- Katzung, B. G. (2017). Basic and clinical pharmacology. McGraw-Hill Education.
- Lehne, R. A., Moore, L. A., Crosby, L. J., & Hamilton, D. B. (2004). Pharmacology for nursing care.
- Smeltzer, S. C., & Bare, B. G. (1992). Brunner & Suddarth’s textbook of medical-surgical nursing. Philadelphia: JB Lippincott.
- Zasadzinski, J. A., Ding, J., Warriner, H. E., Bringezu, F., & Waring, A. J. (2001). The physics and physiology of lung surfactants. Current Opinion in Colloid & Interface Science, 6(5-6), 506-513. [Link]